When the stock market experiences a sharp decline, as it did after the Trump administration announced tariffs on its trade partners and China responded with retaliatory tariffs, many investors start ...

Den amerikanske lægemiddelsstyrelse FDA har accepteret en ansøgning fra Novo Nordisk om at markedsføre en pilleversion af fedmemidlet Wegovy. Det skriver Novo ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Danskerne fravælger Tesla, medvind til Netcompany og Novo Nordisk, der indgår vigtig aftale i USA. Det er blot nogle af overskrifterne i dagens update fra Berlingske Business. Det er blevet torsdag og ...

Det øgede salg i første kvartal får ikke Eli Lilly til at ændre ved prognosen om et samlet salg på mellem 58 og 61 milliarder dollar for hele 2025. Eli Lillys aktie falder trods omsætningsfremgangen ...

Novo Nordisk scored a huge legal victory that largely restricts ... It's very good for people who keep their heads Expect a ...

Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...

While the UK market was closed on Monday for the Easter bank holiday, US stocks sold off as president Donald Trump hurled ...

BMO also downgraded the Danish pharma developer’s rating. Novo Nordisk Stock Under Fire After BMO Cuts Rating and Target Price In addition to lowering its price target from $105 to $64 to market ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...